300 related articles for article (PubMed ID: 24036854)
21. Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer.
Talekar M; Ouyang Q; Goldberg MS; Amiji MM
Mol Cancer Ther; 2015 Jul; 14(7):1521-31. PubMed ID: 25964202
[TBL] [Abstract][Full Text] [Related]
22. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
Engel J; Emons G; Pinski J; Schally AV
Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
[TBL] [Abstract][Full Text] [Related]
23. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance.
Patil YB; Swaminathan SK; Sadhukha T; Ma L; Panyam J
Biomaterials; 2010 Jan; 31(2):358-65. PubMed ID: 19800114
[TBL] [Abstract][Full Text] [Related]
24. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK
Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553
[TBL] [Abstract][Full Text] [Related]
25. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
Nagy A; Schally AV
Biol Reprod; 2005 Nov; 73(5):851-9. PubMed ID: 16033997
[TBL] [Abstract][Full Text] [Related]
26. PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer.
Risnayanti C; Jang YS; Lee J; Ahn HJ
Sci Rep; 2018 May; 8(1):7498. PubMed ID: 29760419
[TBL] [Abstract][Full Text] [Related]
27. Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy.
Garbuzenko OB; Kuzmov A; Taratula O; Pine SR; Minko T
Theranostics; 2019; 9(26):8362-8376. PubMed ID: 31754402
[TBL] [Abstract][Full Text] [Related]
28. Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging?
Saad M; Garbuzenko OB; Ber E; Chandna P; Khandare JJ; Pozharov VP; Minko T
J Control Release; 2008 Sep; 130(2):107-14. PubMed ID: 18582982
[TBL] [Abstract][Full Text] [Related]
29. Multifunctional Liposomes Enable Active Targeting and Twinfilin 1 Silencing to Reverse Paclitaxel Resistance in Brain Metastatic Breast Cancer.
Du J; Shao Y; Hu Y; Chen Y; Cang J; Chen X; Pei W; Miao F; Shen Y; Muddassir M; Zhang Y; Zhang J; Teng G
ACS Appl Mater Interfaces; 2021 May; 13(20):23396-23409. PubMed ID: 33982563
[TBL] [Abstract][Full Text] [Related]
30. In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses.
Arencibia JM; Schally AV; Halmos G; Nagy A; Kiaris H
Anticancer Drugs; 2001 Jan; 12(1):71-8. PubMed ID: 11272290
[TBL] [Abstract][Full Text] [Related]
31. Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer.
Gao Y; Foster R; Yang X; Feng Y; Shen JK; Mankin HJ; Hornicek FJ; Amiji MM; Duan Z
Oncotarget; 2015 Apr; 6(11):9313-26. PubMed ID: 25823654
[TBL] [Abstract][Full Text] [Related]
32. Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes.
Taratula O; Garbuzenko O; Savla R; Wang YA; He H; Minko T
Curr Drug Deliv; 2011 Jan; 8(1):59-69. PubMed ID: 21034421
[TBL] [Abstract][Full Text] [Related]
33. The development, characterization and in vivo anti-ovarian cancer activity of poly(propylene imine) (PPI)-antibody conjugates containing encapsulated paclitaxel.
Jain NK; Tare MS; Mishra V; Tripathi PK
Nanomedicine; 2015 Jan; 11(1):207-18. PubMed ID: 25262579
[TBL] [Abstract][Full Text] [Related]
34. Blocking Stemness and Metastatic Properties of Ovarian Cancer Cells by Targeting p70
Ma J; Kala S; Yung S; Chan TM; Cao Y; Jiang Y; Liu X; Giorgio S; Peng L; Wong AST
Mol Ther; 2018 Jan; 26(1):70-83. PubMed ID: 29241971
[TBL] [Abstract][Full Text] [Related]
35. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
Jeong JY; Kim KS; Moon JS; Song JA; Choi SH; Kim KI; Kim TH; An HJ
Apoptosis; 2013 Apr; 18(4):509-20. PubMed ID: 23371322
[TBL] [Abstract][Full Text] [Related]
36. Chemokine CCL20 promotes the paclitaxel resistance of CD44
Chen M; Su J; Feng C; Liu Y; Zhao L; Tian Y
Mol Med Rep; 2021 Sep; 24(3):. PubMed ID: 34278466
[TBL] [Abstract][Full Text] [Related]
37. Xiaoaiping injection enhances paclitaxel efficacy in ovarian cancer via pregnane X receptor and its downstream molecules.
Zhang XQ; Ding YW; Chen JJ; Xiao X; Zhang W; Zhou L; Kong QW; Shi MZ; Yang J; Jiang B; Guo C; Han YL
J Ethnopharmacol; 2020 Oct; 261():113067. PubMed ID: 32505840
[TBL] [Abstract][Full Text] [Related]
38. Effect of gonadotropin-releasing hormone agonist on ES-2 ovarian cancer cells.
Tsui KH; Lee WL; Seow KM; Yang LW; Wang SY; Wang PH; Chang CL; Yen MS; Cheng JT; Chen CP
Taiwan J Obstet Gynecol; 2014 Mar; 53(1):35-42. PubMed ID: 24767644
[TBL] [Abstract][Full Text] [Related]
39. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
40. Natural Particulates Inspired Specific-Targeted Codelivery of siRNA and Paclitaxel for Collaborative Antitumor Therapy.
Wang R; Zhao Z; Han Y; Hu S; Opoku-Damoah Y; Zhou J; Yin L; Ding Y
Mol Pharm; 2017 Sep; 14(9):2999-3012. PubMed ID: 28753317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
